Premium
Survival of patients with localized prostate cancer treated with percutaneous transperineal placement of radioactive gold seeds: Stages A2, B, and C
Author(s) -
Hochstetler Jerald A.,
Kreder Karl J.,
Loening Stefan A.,
Brown C. Kice
Publication year - 1995
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990260607
Subject(s) - medicine , prostate cancer , prostate , urology , cancer , percutaneous , brachytherapy , oncology , gynecology , surgery , radiation therapy
Between 1984 and 1991, a total of 177 patients with adenocarcinoma of the prostate were treated with transcutaneous, transperineal radioactive gold seeds. Of these 177 patients, 20 were determined to have pelvic lymph node involvement and were excluded from this review. The remaining 157 patients received a median radioactivity dose of 164 mCi with a median follow‐up of 48 months. Cancer‐specific survival at 5 years was 100% for stage A2 and B1, 90% for stage B2, and 76% for stage C cancer. Covariates of grade, total radioactivity administered, age of the patient, and number of seeds implanted did not influence disease‐free survival in a statistically significant manner. Significant complications were observed in two patients. The survival rates of patients treated with 198 Au seed implanation for localized cancer are equivalent or better when compared to historical data of patients treated with 125 I implantation, external beam radiotherapy, combination radioactive gold seed implantation and external irradiation, and radical prostatectomy. In addition, these comparable survival rates using intersitial 198 Au seeds may be achieved with less morbidity.